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Abstract
Background:  Alopecia  areata  is  an  autoimmune  disease  that  produces  non-scarring  hair  loss
around the  body.  Gene  variants  of  the  cytotoxic  T-lymphocyte  antigen  4  (CTLA4)  gene,  a  neg-
ative regulator  of  T-cell  response,  have  been  associated  with  a  predisposition  to  autoimmune
diseases in  different  populations;  however,  the  involvement  of  these  genetic  variants  in  the
development  of  AA  is  controversial.
Objective:  The  present  study  evaluated  the  potential  association  of  two  CTLA4  gene  variants
with alopecia  areata  in  a  Mexican  population.
Methods:  We  genotyped  +49AG  (rs231775)  and  CT60  (rs3087243)  variants  in  50  AA  patients  and
100 healthy  control  participants  through  PCR-RFLP.
Results:  No  statistical  difference  was  observed  for  either  of  the  gene  variants  regarding
allele or  genotype  frequencies  between  AA  patients  and  the  controls  when  the  parameters
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of  family/personal  history  of  autoimmune  diseases  or  gender  were  considered  (p  >  0.05).
Study limitations:  Small  sample  size  of  patients  and  the  data  were  obtained  from  Northeast
Mexico population.
Conclusion:  The  genetic  variants  rs231775  and  rs3087243  of  the  CTLA4  gene  are  not  a  risk  factor
for the  development  of  alopecia  areata  in  the  analyzed  Mexican  population.
© 2020  Sociedade  Brasileira  de  Dermatologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY  license  (http://creativecommons.org/licenses/by/4.0/).
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power  of  99.0%  (a  Z  value  of  2.33),  a  minimum  number  of
43  subjects  is  sufficient.
Data  analysis  was  performed  with  the  SPSS  v21.0  soft-
ware  for  windows  (SPSS,  Inc.,  Chicago,  IL,  USA)  and  the
Table  1  Tests  for  deviation  from  Hardy--Weinberg  equilib-
rium  in  AA  patients  and  healthy  controls.
SNP/HWE  test  AA  cases
(p-value)
Controls
(p-value)
rs231775
Pearson  0.81  0.88
Likelihood-ratio  0.81  0.88
Fisher  exact  0.78  1.00
rs3087243ntroduction
lopecia  areata  (AA)  is  an  autoimmune  disease  that  pro-
uces  non-scarring  hair  loss  through  the  body  at  any  age.1
A  is  commonly  presented  as  single  or  multiple  rounded
atches,  although  complete  baldness  may  occur,  which  is
alled  AA  totalis.  If  the  hair  loss  occurs  throughout  the
ody  is  known  as  AA  universalis.  AA  can  also  be  presented
s  in  the  circumference  of  the  head  and  is  known  as  AA
phis.2 AA  is  considered  a  polygenic  disease  influenced  by  a
enetically  complex  inheritance,  especially  of  autoimmune
nd  inflammatory  related  genes,  along  with  environmen-
al  factors.3,4 Various  genes  of  the  immune  system  have
een  reported  to  contribute  to  the  development  of  this  dis-
ase,  such  as  the  autoimmune  regulator  (AIRE)  gene,  human
eukocyte  antigen  (HLA),  interleukin  (IL)  genes,  cytotoxic  T
ymphocyte-associated  antigen  4  (CTLA4),  protein  tyrosine
hosphatase  non-receptor  type  22  (PTPN22),  tumor  necrosis
actor  superfamily  member  6  or  CD95  (FAS)  and  FAS  ligand
FASL)  among  others.5,6
The  cytotoxic  T-lymphocyte  antigen  4  (CTLA4)  gene
2q34)  is  a  member  of  the  immunoglobulin  superfamily
ncoding  a  protein  whose  function  is  that  of  a  potent  neg-
tive  regulator  of  T-cell  response.  Also  involved  in  the
aintenance  of  immune  tolerance,  it  has  been  implicated
s  a  susceptibility  gene  in  human  autoimmune  diseases,  pre-
enting  several  polymorphisms  that  have  been  associated
ith  its  development.7 Among  the  latter,  two  genetic  vari-
nts  may  contribute  to  AA  susceptibility:  +49AG  (rs231775),
 missense  variation  leading  to  a  threonine  to  alanine
minoacid  substitution  at  codon  17  in  the  leader  peptide
T17A);  and  CT60  (rs3087243),  located  236  bp  downstream
f  CTLA4  gene  (3′-UTR).8 However,  recent  studies  conducted
n  different  populations  have  shown  that  the  relationship
f  these  genetic  variants  in  the  development  of  AA  is
ontroversial.3,9
The  current  study  sought  to  determine  whether  the
TLA4  +49AG  (rs231775)  and  CT60  (rs3087243)  gene  vari-
nts  constitute  a  predisposition  factor  for  AA  in  a  cohort  of
exican  patients.
ethods
election  of  subjects  and  controlshe  study  included  50  unrelated  Mexican  subjects  diagnosed
ith  AA  (32  females  and  18  males;  30  ±  15  years  old  on  aver-
ge)  and  100  healthy  control  participants  (59  females  and  41
ales;  25  ±  8  years  old  on  average),  the  latter  showed  a neg-tive  medical  family  history  for  autoimmune/inflammatory
iseases.  The  patients  were  recruited  from  the  Dermatol-
gy  Department  after  the  acceptance  and  signature  of  an
nformed  consent.  Ethical  approval  was  given  by  the  Insti-
utional  Review  Board  and  this  study  was  registered  under
he  code  DE09-001.  Further  details  regarding  the  clinical
nd  demographic  characteristics,  AA  type  and  distribution  of
ach  patient  were  obtained  during  the  clinical  evaluation.
NA  isolation  and  genotyping
enomic  DNA  was  isolated  from  peripheral  venous  blood
sing  a  ‘‘salting-out’’  method  and  suspended  in  Tris--EDTA
pH  7.8)  at  a  final  concentration  0.1--1.0  g/L  before
se.  Genotype  and  allele  frequencies  of  the  CTLA4  +49AG
rs231775)  andCT60  (rs3087243)  gene  variants  were  cha-
acterized  by  PCR-RFLP  using  a  MJ  Mini  PTC1148  thermal
ycler  (Bio-Rad,  Hercules;  CA,  USA),  specific  oligonucleotide
rimers  (IDT,  Coralville,  IA,  USA)  and  restriction  enzymes
New  England  Biolabs,  Ipswich,  MA,  USA)  according  to  a  pre-
iously  published  protocol.10 The  fragments  obtained  were
nalyzed  by  electrophoresis  in  a  2.5%  agarose  gel  containing
thidium  bromide,  visualized  in  UVP  model  2UV  High  Perfor-
ance  Transilluminator  (Upland,  CA,  USA)  and  documented.
tatistical  analysis
or  genetic  analysis,  the  sample  size  was  calculated  based
n  2%  worldwide  alopecia  areata  incidence,11 assuming  aPearson  0.89  0.50
Likelihood-ratio  0.89  0.50
Fisher  exact  1.00  0.54
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Table  2  Allele  and  genotype  frequency  of  the  gene  variants  CTLA4  +49AG  (rs231775)  and  CT60  (rs3087243)  in  AA  patients  and
healthy controls.
Genotype  AA  patients  no.  (%)  Controls  no.  (%)  2 OR  95%  CI  p-Value
All  AA  types rs231775
AA  15  (30)  28  (28.3)  0.086  0.958
AG 24  (48)  50  (50.5)
GG 11  (22)  21  (21.2)
AG +  GG  24  (48)  +  11  (22)  50  (50.5)  +  21  (21.2)  0.048  1.087  0.515--2.292  0.827
Alleles
A 54  (54)  106  (53.5)  0.006  1.019  0.629--1.650  0.939
G 46  (46)  92  (46.5)  0.006  0.982  0.606--1.590  0.939
Patchy AA
AA  13  (31.7)  28  (28.3)  0.225  0.893
AG 19  (46.3)  50  (50.5)
GG 9  (22)  21  (21.2)
AG +  GG  19  (46.3)  +  9  (22)  50  (50.5)  +  21  (21.2)  0.164  1.177  0.534--2.594  0.685
Alleles
A 45  (54.9)  106  (53.5)  0.042  1.056  0.630--1.770  0.837
G 37  (45.1)  92  (46.5)  0.042  0.947  0.565--1.589  0.837
Multiple patch  AA
AA  11  (40.7) 28  (28.3) 1.66 0.436
AG 12  (44.5) 50  (50.5)
GG 4  (14.8)  21  (21.2)
AG +  GG  12  (44.5)  +  4  (14.8)  50  (50.5)  +  21  (21.2)  1.541  1.743  0.721--4.218  0.215
Alleles
A 34  (63)  106  (53.5)  1.527  1.476  0.795--2.740  0.217
G 20  (37)  92  (46.5)  1.527  0.678  0.365--1.259  0.217
All AA  types  rs3087243
AA  6  (12)  16  (16)  2.129  0.345
AG 22  (44)  52  (52)
GG 22  (44)  32  (32)
AG +  GG  22  (44)  +  22  (44)  52  (52)  +  32  (32)  0.426  0.716  0.262--1.959  0.514
Alleles
A 34  (34) 84  (42)  1.788  0.711  0.432--1.173  0.181
G 66  (66) 116  (58) 1.788  1.406  0.853--2.318  0.181
Patchy AA
AA  6  (14.6)  16  (16)  1.168  0.558
AG 18  (43.9)  52  (52)
GG 17  (41.5)  32  (32)
AG +  GG  18  (43.9)  +  17  (41.5)  52  (52)  +  32  (32)  0.041  0.9  0.325--2.49  0.839
Alleles
A 30  (36.6)  84  (42)  0.708  0.797  0.469--1.353  0.4
G 52  (63.4)  116  (58)  0.708  1.255  0.739--2.132  0.4
Multiple patch  AA
AA  4  (14.8)  16  (16)  0.031  0.985
AG 14  (51.9)  52  (52)
GG 9  (33.3)  32  (32)
AG +  GG  14  (51.9)  +  9  (33.3)  52  (52)  +  32  (32)  0.023  0.913  0.278--2.998  0.881
Alleles
A 22  (40.7)  84  (42)  0.028  0.949  0.515--1.749  0.868
G 32  (59.3)  116  (58)  0.028  1.053  0.572--1.941  0.868
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Table  3  Analysis  of  the  gene  variants  CTLA4  +49AG  (rs231775)  and  CT60  (rs3087243)  frequencies  with  the  sex  and  per-
sonal/familiar  history  of  autoimmune  diseases.
AA  AG  GG  p-Value  AA  AG  GG  p-Value
Sex
Female  (%)  8  (25%)  16  (50%)  8  (25%)  0.555  4  (12.5%)  14  (43.75%)  14  (43.75%)  0.990
Male (%)  7  (38.9%)  8  (44.4%)  3  (16.7%)  2  (11.2%)  8  (44.4%)  8  (44.4%)
Personal history  of  autoimmune  diseases
Yes (%)  3  (30%)  3  (30%)  4  (40%)  0.261  1  (10%)  3  (30%)  6  (60%)  0.515
No (%)  12  (30%)  21  (52.5%)  7  (17.5%)  5  (12.5%)  19  (47.5%)  16  (40%)
Familiar history  of  autoimmune  diseases
Yes  (%)  10  (27.8%)  19  (52.8%)  7  (19.4%)  0.548  4  (11.1%)  17  (47.2%)  15  (41.7%)  0.761
No (%) 5  (38.4%)  4  (30.8%)  4  (30.8%)  2  (14.3%)  5  (35.7%)  7  (50%)
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bpi-INFO  TM  7  statistical  program  (Stone.  Mountain,  GA,
SD  Inc).  Hardy--Weinberg  equilibrium  for  the  alleles  was
btained  using  a  goodness-of-fit  test  and  the  genotypic
ependence  between  patients  and  controls  was  determined
ith  a  2 test;  OR  was  calculated  from  2  ×  2  contingency
ables  (p  <  0.05).
esults
linical  characteristics  of  the  participants
he  present  study  analyzed  the  genotype  distribution  and
llele  frequency  of  CTLA4  +49AG  and  CT60  gene  variants.
ur  universe  (n)  consisted  of  50  AA  patients  and  100  control
articipants.  The  clinical  presentation  of  AA  in  the  patients
as:  41  Patchy  AA  subjects  (single  patch  n  =  14,  8  females
nd  6  males;  multiple  patches  n  =  27,  19  females  and  8
ales),  4  Ophiasis  AA  subjects  (3  females  and  1  male),  1
emale  with  Totalis  AA  and  4  Universalis  AA  subjects  (3  males
nd  1  female).  Ten  patients  (20%)  had  a  personal  history  of
utoimmune  diseases  (Vitiligo,  type  2  DM,  among  others)  and
6  subjects  (72%)  have  family  history  of  immune  disease.
llele  and  genotype  analysis
everal  tests  were  performed  for  both  genetic  variants
n  order  to  assess  the  Hardy--Weinberg  equilibrium  (HWE)
Table  1)  all  of  which  had  a  p  >  0.05,  indicating  that  rs231775
nd  rs3087243  gene  variants  were  in  HWE  in  both  AA  patients
nd  controls.
We  compared  the  CTLA4  rs231775  and  the  rs3087243  alle-
es  and  genotypes  of  the  control  group  with  AA  subjects
all  AA  types),  and  with  the  different  types  of  AA,  detailed
esults  are  shown  in  table  1.  For  CTLA4  rs231775,  30%  of
A  patients  showed  an  homozygous  wild  type  AA  genotype,
8%  showed  the  heterozygous  AG  genotype,  and  the  remain-
ng  22%  were  variant  homozygous  GG  genotype.  For  CTLA4
s3087243,  44%  of  the  AA  patients  showed  the  homozygous
ild  type  GG  genotype,  44%  showed  the  heterozygous  AG
enotype  and  the  remaining  12%  were  variant  homozygous
A  genotype.
t
s
rssociation  of  the  genotypes  in  patients  con
lopecia areata
hen  CTLA4  rs231775  and  rs3087243  genotypes  and  allele
requencies  were  compared  between  the  whole  cohort  (all
A  types)  and  controls,  we  observed  that  the  heterozygous
G  genotype  for  CTLA4  rs231775  and  rs3087243  was  more
requent  in  controls  than  across  all  AA  patient  groups.  Fur-
her,  no  evidence  was  observed  concerning  the  association  of
he  allele  variants  and  AA  in  the  analyzed  patients  (p  >  0.05)
Table  2).  Furthermore,  no  relationship  was  found  between
enotype  and  type  of  AA  with  the  personal/familiar  history
f  autoimmune  diseases  or  the  sex  of  the  analyzed  patients
p  >  0.05)  (Table  3).
iscussion
A  is  an  autoimmune  hair-loss  condition  that  has  been
ssociated  with  multiple  gene  variants,  several  of  which  par-
icipate  in  immune  response  pathways  related  to  HLA.12 The
TLA4  gene  product  is  a  receptor  expressed  by  CD4+  and
D8+  T-cells.  Experiments  in  knockout  mice  have  demon-
trated  the  important  role  that  CTLA4  plays  in  protection
gainst  autoimmunity.  CTLA-4  is  a  critical  negative  regula-
or  of  T  cell  responses,  and  the  action  of  CTLA4  on  Treg  cells
an  control  the  activity  of  other  cells  and  controlling  fatal
utoimmunity.13
The  association  between  the  presence  of  the  CTLA4
ene  variants  and  the  development  of  different  autoimmune
iseases  has  been  suggested.14,15 However  in  immune  der-
atological  diseases,  the  results  have  been  controversial;
n  vitiligo  their  participation  or  lack  of  influence16 has  been
een.  A  similar  situation  has  been  observed  with  the  devel-
pment  of  psoriasis.17,18
In  this  regard,  considering  the  possible  contribution  of
he  autoimmune  function  in  alopecia,  genetic  variant  stud-
es  of  CTLA4  gene  have  been  explored  in  diverse  populations.
 previous  association  analysis  has  suggested  the  plausi-
le  involvement  of  CTLA4  gene  variants  as  a  risk  factor  in
he  development  of  AA  in  a  European  population,8 with  a
tronger  effect  in  patients  with  severe  forms  of  the  disorder.
Another  study  conducted  on  an  Italian  population,  where
s231775  and  rs3087243  gene  variants  were  analyzed,
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1CTLA4  +49AG  and  CT60  gene  variants  are  not  associated  wit
observed  the  latter  as  a  risk  factor  in  the  development  of
patchy  AA.9 On  the  other  hand,  a  study  conducted  on  Iran
nationals  failed  to  prove  the  association  of  the  rs3087243
gene  variant  in  the  development  of  AA.3
Previously,  we  observed  the  participation  of  genetic  vari-
ants  of  TNF and  PTPN2219 as  a  risk  factor  for  AA  in  Mexican
patients;  both  of  these  genes’  function  is  related  to  the  reg-
ulation  of  immune  mechanisms.  However,  the  participation
of  CTLA4  genetic  variants  in  AA  has  not  been  analyzed  in  this
population.
Some  SNPs  within  the  CTLA-4  gene  have  already  been
analyzed  for  susceptibility  to  rheumatoid  arthritis  (RA)  in  the
Mexican  population;  among  them,  rs5742909,  rs231775  and
rs3087243,  suggesting  that  the  −319C/+49G/CT60G  haplo-
type  of  the  CTLA-4  gene  is  a  risk  factor  for  RA,  whereas  that
the  rs3087243  SNP  could  be  a  protective  factor  against  this
type  of  autoimmune  disease.20
However,  no  significant  differences  were  observed  for
rs231775  and  rs3087243  in  our  study  population  (Table  2),
suggesting  that  these  variants  are  not  a  risk  factor  in  the
development  of  AA  or  Patchy  AA  in  the  Mexican  population.
Conclusion
In  conclusion,  the  genetic  variants  rs231775  and  rs3087243
of  the  CTLA4  gene  do  not  constitute  a  risk  factor  in  the
development  of  AA  in  the  Mexican  population  of  Monterrey,
Mexico.  Further,  these  genetic  variants  have  no  association
between  family/personal  backgrounds  of  autoimmune  dis-
eases  or  the  gender  of  the  study  subjects.
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